Biopharmaceutical company GSK plc (LSE/NYSE:GSK) announced on Tuesday that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its investigational B7-H3-targeted antibody-drug conjugate (ADC), GSK5764227 (GSK'227), for the treatment of relapsed or refractory extensive-stage small-cell lung cancer (ES-SCLC).
This designation is based on promising early clinical data demonstrating the potential of GSK'227 to significantly improve outcomes for patients with this aggressive and difficult-to-treat cancer.
GSK acquired global rights to GSK'227 from Hansoh Pharma (HKG:3692) earlier this year. The company plans to initiate global phase 1/2 trials in the second half of 2024 to support a registrational pathway for GSK'227.
Breakthrough Therapy Designation aims to expedite the development and review of drugs with the potential to offer an improvement over available therapies for serious conditions.
BerGenBio reveals preliminary safety data from Phase 1b BGBC016 study in first-line NSCLC patients
Liquidia and Pharmosa expand collaboration for inhaled treprostinil
Sanofi and Regeneron's Dupixent approved for COPD in China
Alvotech launches confirmatory study for Entyvio biosimilar
Merck's KEYTRUDA receives new approvals in Japan for lung and urothelial cancers
Innate Pharma receives FDA clearance of IND for IPH4502, a Nectin-4 targeting ADC for solid tumours
Intas Pharmaceuticals reports positive opinion for HETRONIFLY in Europe
Insilico Medicine reveals positive preliminary results from ISM001-055Phase IIa clinical trial
NeoGenomics to present breakthrough data at ESMO 2024 on ctDNA and NGS for cancer diagnostics
OSE Immunotherapeutics initiates Phase 3 trial for cancer vaccine Tedopi